Log In Get Started
Insider Trading April 20, 2026 01:04 PM

Saba Capital Disposes $1.87 Million in BlackRock ECAT Shares Over Two Days

127,748 shares sold April 16-17 as the trust continues to trade near $14.57 with a double-digit dividend yield

By Jordan Park ECAT
Saba Capital Disposes $1.87 Million in BlackRock ECAT Shares Over Two Days
ECAT

Saba Capital Management, L.P., a reported ten percent holder of BlackRock ESG Capital Allocation Term Trust (NASDAQ: ECAT), sold 127,748 shares of the trust's common stock on April 16 and April 17, 2026, for about $1.87 million. The shares were sold at prices between $14.51 and $14.69. After the transactions, Saba still indirectly holds 21,528,182 shares. ECAT is trading around $14.57, carries a 22.42% dividend yield and a market capitalization of $1.46 billion, and has returned 25% over the past year. InvestingPro Tips note that ECAT has increased its dividend for five consecutive years and provides a substantial payout to shareholders.

Key Points

  • Saba Capital sold 127,748 shares of BlackRock ESG Capital Allocation Term Trust common stock on April 16-17, 2026, totaling about $1.87 million.
  • Sale prices ranged from $14.51 to $14.69; the trust was quoted at $14.57 and shows a 22.42% dividend yield and a market cap of $1.46 billion.
  • After the transactions, Saba indirectly retains 21,528,182 shares; ECAT has returned 25% over the past year and has reportedly raised its dividend for five consecutive years.

Saba Capital Management, L.P. reported the disposal of common shares in BlackRock ESG Capital Allocation Term Trust (NASDAQ: ECAT), totaling approximately $1.87 million. The filing shows the transactions took place on April 16 and April 17, 2026.

The firm sold 127,748 shares of ECAT common stock. Executed prices ranged from $14.51 to $14.69 per share. As of the most recent quote referenced in the filing, the trust trades at $14.57 and offers a dividend yield of 22.42%.

Following these sales, Saba Capital Management, L.P. indirectly holds 21,528,182 shares of BlackRock ESG Capital Allocation Term Trust common stock. The trust has a market capitalization of $1.46 billion and has produced a 25% return over the last 12 months.

The filing also references InvestingPro Tips commentary indicating ECAT has raised its dividend for five consecutive years and distributes a significant dividend to shareholders. The InvestingPro note highlights the availability of two additional ProTips and deeper financial metrics on that platform.

Transaction details and the trust's public metrics are presented without further explanation in the filing. The report does not provide commentary from Saba Capital, BlackRock, or other parties explaining the motivation for the sales or outlining any changes to Saba's broader investment strategy.

Contextual summary - The disclosure records a two-day sale by a substantial shareholder of a closed-end fund. The reported prices and the current trading price are within a narrow range, and the fund's stated dividend yield and recent one-year return are cited as prominent metrics in the filing.

What remains unspecified - The filing does not state the reason for the sales, whether they were part of a pre-existing plan, or whether additional sales are planned. No statements from the trust or the seller accompany the transaction data.

This report is a factual account of the transaction and related fund metrics as presented in the disclosure. It does not attempt to draw conclusions beyond the information the filing supplies.

Risks

  • The filing does not disclose Saba Capital's motivation for the sales, creating uncertainty about whether the transactions reflect portfolio rebalancing, liquidity needs, or other objectives - this impacts investors tracking insider activity and sentiment in asset management and financial markets.
  • Price variability is present within the reported trade range ($14.51 to $14.69) and relative to the current quote ($14.57), indicating potential short-term share price movement risk for income-focused investors in closed-end funds.
  • Access to the two additional InvestingPro ProTips and the referenced financial metrics requires use of that platform, which may limit immediate public access to the extra analytics cited in the filing.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026